Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease (NEJM)

A phase 3b trial compared risankizumab with ustekinumab in patients with moderate-to-severe Crohn’s disease. Patients were treated for 48 weeks after inadequate response or unacceptable side effects from anti-TNF therapy. Risankizumab was noninferior in achieving clinical remission at 24 weeks (58.6% vs. 39.5%) and superior in endoscopic remission at 48 weeks (31.8% vs. 16.2%). Both drugs had similar adverse event rates. The study was funded by AbbVie.